GENFIT
Company discovering and developing innovative therapeutic and diagnostic solutions targeting liver diseases.
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments.
GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease.
Visit website: https://www.genfit.com/
Details last updated 27-Feb-2021
GENFIT News
10 Hot European Biotechs to watch in 2016
Labiotech - 12-Jan-2016
Including immuno-oncology treatments, antibody delivery, Tau-aggregation inhibitors and mRNA ther...
Read more...